Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress

About this update from Eisai Co., Ltd.

[{"type":"text","content":"STOCKHOLM, March 11, 2026 /PRNewswire/ -- BioArctic's AB (publ) (STOCKHOLM: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, and online. In addition, BioArctic will have an oral presentation on lecanemab and a poster presentation relating to exidavnemab at the conference. ","length":489,"tagName":"p"},{"type":"text","content":"Eisai will present lecanemab data focused on real-world efficacy and safety, as well as four-year data from the Clarity AD Open-Label Extension trial. Eisai will also host one industry-sponsored symposium.","length":205,"tagName":"p"},{"type":"text","content":"Professor Lars Lannfelt, BioArctic's co-founder, will hold an oral presentation regarding the mechanisms of action and binding profile of lecanemab. BioArctic will also present a poster related to exidavnemab in Parkinson's disease.","length":240,"tagName":"p"},{"type":"text","content":"Lecanemab is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease.","length":249,"tagName":"p"},{"type":"text","content":"Presentations by BioArctic and Eisai","length":36,"tagName":"p"},{"type":"text","content":"Oral presentations","length":18,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.67em;VERTICAL-ALIGN:BOTTOM;","val":[{"type":"text","content":"Asset, session, presentation time","length":33,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.67em;VERTICAL-ALIGN:BOTTOM;","val":[{"type":"text","content":"Presentation title","length":18,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.67em;VERTICAL-ALIGN:BOTTOM;","val":[{"type":"text","content":"Lecanemab","length":9,"tagName":"p","attribs":{}},{"type":"text","content":"Real-world outcomes and mechanistic insights in anti-amyloid treatment ","length":81,"tagName":"p","attribs":{}},{"type":"text","con...

More updates from Eisai Co., Ltd.